Biological Effects of AL622, a Molecule Rationally Designed to Release an EGFR and a c-Src Kinase Inhibitor

Chemical Biology and Drug Design

Volumn 80, Issue 6, 2012, Pages 981-991

  Larroque Lombard, Anne Laure ^a   Ning, Na ^a   Rao, Suman ^a   Lauwagie, Sylvia ^a   Halaoui, Ruba ^a   Coudray, Laëtitia ^a   Huang, Ying ^a   Jean Claude, Bertrand J ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Chemical biology; Mechanism based drug design; Therapeutic target

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; AL 622; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL; CELL INVASION; CELL MOTILITY; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG DEGRADATION; DRUG DESIGN; DRUG EFFECT; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; FLUORESCENCE MICROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROLYSIS; MOUSE; NONHUMAN; ONCOGENE SRC; PRIORITY JOURNAL;

ADENINE; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DRUG DESIGN; HUMANS; KINETICS; MICE; NIH 3T3 CELLS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SRC-FAMILY KINASES;

EID: 84868031063     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12043     Document Type: Article

References (25)

1. Summy J.M., Gallick G.E. (2003) Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev;22:337-358.
2. Yeatman T.J. (2004) A renaissance for SRC. Nat Rev Cancer;4:470-480.
3. Nautiyal J., Majumder P., Patel B.B., Lee F.Y., Majumdar A.P. (2009) Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. Cancer Lett;283:143-151.
4. Boerner J.L., Demory M.L., Silva C., Parsons S.J. (2004) Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II. Mol Cell Biol;24:7059-7071.
5. Biscardi J.S., Maa M.-C., Tice D.A., Cox M.E., Leu T.-H., Parsons S.J. (1999) c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem;274:8335-8343.
6. Dimri M., Naramura M., Duan L., Chen J., Ortega-Cava C., Chen G., Goswami R., Fernandes N., Gao Q., Dimri G.P., Band V., Band H. (2007) Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior. Cancer Res;67:4164-4172.
7. Lu Y.H., Gao X.Q., Wu M., Zhang-Negrerie D., Gao Q. (2011) Strategies on the development of small molecule anticancer drugs for targeted therapy. Mini Rev Med Chem;11:611-624.
8. Cavazzoni A., Alfieri R.R., Carmi C., Zuliani V., Galetti M., Fumarola C. et al. (2008) Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines. Mol Cancer Ther;7:361-370.
9. Shimizu T., Tolcher A.W., Papadopoulos K.P., Beeram M., Rasco D.W., Smith L.S., Gunn S., Smetzer L., Mays T.A., Kaiser B., Wick M.J., Alvarez C., Cavazos A., Mangold G.L., Patnaik A. (2012) The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res;18:2316-2325.
10. Cai X., Zhai H.X., Wang J., Forrester J., Qu H., Yin L. et al. (2010) Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J Med Chem;53:2000-2009.
11. Hanke J.H., Gardner J.P., Dow R.L., Changelian P.S., Brissette W.H., Weringer E.J., Pollok B.A., Connelly P.A. (1996) Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem;271:695-701.
12. Barker A.J., Gibson K.H., Grundy W., Godfrey A.A., Barlow J.J., Healy M.P., Woodburn J.R., Ashton S.E., Curry B.J., Scarlett L., Henthorn L., Richards L. (2001) Studies leading to the identification of ZD1839 (iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett;11:1911-1914.
13. Barchechath S., Williams C., Saade K., Lauwagie S., Jean-Claude B. (2009) Rational design of multitargeted tyrosine kinase inhibitors: a novel approach. Chem Biol Drug Des;73:380-387.
14. Hanefeld U., Rees C.W., White A.J.P., Williams D.J. (1996) One-pot synthesis of tetrasubstituted pyrazoles - proof of regiochemistry. J Chem Soc, Perkin Trans 1;13:1545-1552.
15. Brahimi F., Matheson S.L., Dudouit F., McNamee J.P., Tari A.M., Jean-Claude B.J. (2002) Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-Triazene" BJ2000, a new probe for Combi-Targeting postulates. J Pharmacol Exp Ther;303:238-246.
16. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst;82:1107-1112.
17. Jallal H., Valentino M.L., Chen G., Boschelli F., Ali S., Rabbani S.A. (2007) A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res;67:1580-1588.
18. Banerjee R., Huang Y., McNamee J.P., Todorova M., Jean-Claude B.J. (2010) The combi-targeting concept: selective targeting of the epidermal growth factor receptor- and Her2-expressing cancer cells by the complex combi-molecule RB24. J Pharmacol Exp Ther;334:9-20.
19. Qiu Q., Domarkas J., Banerjee R., Merayo N., Brahimi F., McNamee J.P., Gibbs B.F., Jean-Claude B.J. (2007) The combi-targeting concept: in vitro and in vivo fragmentation of a stable combi-nitrosourea engineered to interact with the epidermal growth factor receptor while remaining DNA reactive. Clin Cancer Res;13:331-340.
20. Rachid Z., Brahimi F., Domarkas J., Jean-Claude B.J. (2005) Synthesis of half-mustard combi-molecules with fluorescence properties: correlation with EGFR status. Bioorg Med Chem Lett;15:1135-1138.
21. Rachid Z., Brahimi F., Katsoulas A., Teoh N., Jean-Claude B.J. (2003) The combi-targeting concept: chemical dissection of the dual targeting properties of a series of "combi-triazenes". J Med Chem;46:4313-4321.
22. Qiu Q., Domarkas J., Banerjee R., Katsoulas A., McNamee J.P., Jean-Claude B.J. (2007) Type II combi-molecules: design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05. Anticancer Drugs;18:171-177.
23. Biscardi J.S., Belsches A.P., Parsons S.J. (1998) Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells. Mol Carcinog;21:261-272.
24. Biscardi J.S., Ishizawar R.C., Silva C.M., Parsons S.J. (2000) Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res;2:203-210.
25. Silva C.M. (2004) Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene;23:8017-8023.